Bayer AG (BAYRY)
7.05
+0.01
(+0.14%)
USD |
OTCM |
Apr 19, 15:43
Bayer Cash from Financing (TTM): -735.09M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -735.09M |
September 30, 2023 | -424.55M |
June 30, 2023 | -1.554B |
March 31, 2023 | -3.872B |
December 31, 2022 | -4.450B |
September 30, 2022 | -4.238B |
June 30, 2022 | -2.055B |
March 31, 2022 | -5.609B |
December 31, 2021 | -6.679B |
September 30, 2021 | -6.131B |
June 30, 2021 | -3.728B |
March 31, 2021 | 579.52M |
December 31, 2020 | 483.08M |
September 30, 2020 | -2.957B |
June 30, 2020 | -7.331B |
March 31, 2020 | -8.025B |
December 31, 2019 | -9.391B |
September 30, 2019 | -7.622B |
June 30, 2019 | -17.58B |
March 31, 2019 | 27.06B |
December 31, 2018 | 27.67B |
September 30, 2018 | 28.77B |
June 30, 2018 | 39.79B |
March 31, 2018 | -3.495B |
December 31, 2017 | -2.130B |
Date | Value |
---|---|
September 30, 2017 | 3.278B |
June 30, 2017 | 2.406B |
March 31, 2017 | -644.39M |
December 31, 2016 | -387.37M |
September 30, 2016 | -5.559B |
June 30, 2016 | -7.051B |
March 31, 2016 | -3.039B |
December 31, 2015 | -4.410B |
September 30, 2015 | 6.557B |
June 30, 2015 | 12.16B |
March 31, 2015 | 8.349B |
December 31, 2014 | 12.95B |
September 30, 2014 | 2.672B |
June 30, 2014 | -2.267B |
March 31, 2014 | 987.19M |
December 31, 2013 | -3.367B |
September 30, 2013 | -2.420B |
June 30, 2013 | -752.36M |
March 31, 2013 | -5.291B |
December 31, 2012 | -4.864B |
September 30, 2012 | -4.378B |
June 30, 2012 | -5.060B |
March 31, 2012 | -2.444B |
December 31, 2011 | -3.086B |
September 30, 2011 | -3.681B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-17.58B
Minimum
Jun 2019
579.52M
Maximum
Mar 2021
-4.806B
Average
-4.238B
Median
Sep 2022
Cash from Financing (TTM) Benchmarks
Regeneron Pharmaceuticals Inc | -1.790B |
Affimed NV | -6.734M |
InflaRx NV | 57.36M |
MorphoSys AG | -- |
BioNTech SE | -842.92M |